[go: up one dir, main page]

PE20061332A1 - Derivados de piperidina como agentes inhibidores de la renina - Google Patents

Derivados de piperidina como agentes inhibidores de la renina

Info

Publication number
PE20061332A1
PE20061332A1 PE2005001496A PE2005001496A PE20061332A1 PE 20061332 A1 PE20061332 A1 PE 20061332A1 PE 2005001496 A PE2005001496 A PE 2005001496A PE 2005001496 A PE2005001496 A PE 2005001496A PE 20061332 A1 PE20061332 A1 PE 20061332A1
Authority
PE
Peru
Prior art keywords
alkyl
formula
inhibiting agents
piperidine derivatives
renin inhibiting
Prior art date
Application number
PE2005001496A
Other languages
English (en)
Inventor
Werner Breitenstein
Takeru Ehara
Philipp Grosche
Yuki Iwaki
Kazuhide Konishi
Keiichi Masuya
Nils Ostermann
Atsushi Toyao
Fumiaki Yokokawa
Masaki Suzuki
Atsuko Nihonyanagi
Juergen Klaus Maibaum
Takanori Kanazawa
Yuko Hitomi
Claus Ehrhardt
Original Assignee
Novartis Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis Ag filed Critical Novartis Ag
Publication of PE20061332A1 publication Critical patent/PE20061332A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/04—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms
    • C07D295/10—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms
    • C07D295/104—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings
    • C07D295/108—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms with substituted hydrocarbon radicals attached to ring nitrogen atoms substituted by doubly bound oxygen or sulphur atoms with the ring nitrogen atoms and the doubly bound oxygen or sulfur atoms attached to the same carbon chain, which is not interrupted by carbocyclic rings to an acyclic saturated chain
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Urology & Nephrology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Vascular Medicine (AREA)
  • Psychiatry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

REFERIDA A UN COMPUESTO DERIVADO DE PIPERIDINA DE FORMULA I, DONDE R1 ES H, ALQUILO, ALQUENILO, ENTRE OTROS; R2 ES ALQUILO, ALQUENILO, ALQUINILO, ENTRE OTROS; W ES UNA FRACCION DE FORMULA IA, IB O IC; (*) DENOTA UNA POSICION EN DONDE SE ENLAZA LA FRACCION W CON EL ATOMO DE CARBONO-4 EN EL ANILLO DE PIPERIDINA DE FORMULA I; X1, X2, X3, X4 Y X5 SON CARBONO O NITROGENO; y ES UN ENTERO DE 0 A 3; z ES UN ENTERO DE 0 A 4; R3 ES H, ALQUILO C1-C7, ALQUENILO C2-C7, ENTRE OTROS; R4 ES ALQUILO C1-C7, ALQUENILO C2-C7, ENTRE OTROS; T ES METILENO, O CARBONILO; R11 ES H, HIDROXILO, HALOGENO, ENTRE OTROS. TAMBIEN ESTA REFERIDA A UNA FORMULACION FARMACEUTICA Y A UN PROCEDIMIENTO DE PREPARACION. DICHOS COMPUESTOS SON INHIBIDORES DE LA ACTIVIDAD DE LA RENINA Y SON UTILES EN EL TRATAMIENTO DE HIPERTENSION, ATEROESCLEROSIS, SINDROME CORONARIO INESTABLE, ENTRE OTROS
PE2005001496A 2004-12-30 2005-12-16 Derivados de piperidina como agentes inhibidores de la renina PE20061332A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0428526.8A GB0428526D0 (en) 2004-12-30 2004-12-30 Organic compounds

Publications (1)

Publication Number Publication Date
PE20061332A1 true PE20061332A1 (es) 2006-12-27

Family

ID=34179049

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001496A PE20061332A1 (es) 2004-12-30 2005-12-16 Derivados de piperidina como agentes inhibidores de la renina

Country Status (21)

Country Link
US (2) US8084450B2 (es)
EP (2) EP2177518A1 (es)
JP (1) JP5188814B2 (es)
KR (1) KR20070091174A (es)
CN (1) CN101094848B (es)
AR (1) AR052446A1 (es)
AT (1) ATE448217T1 (es)
AU (1) AU2005321475B2 (es)
BR (1) BRPI0519769A2 (es)
CA (1) CA2587348A1 (es)
DE (1) DE602005017665D1 (es)
ES (1) ES2336470T3 (es)
GB (1) GB0428526D0 (es)
GT (1) GT200500359A (es)
MX (1) MX2007008078A (es)
PE (1) PE20061332A1 (es)
PL (1) PL1833816T3 (es)
PT (1) PT1833816E (es)
RU (1) RU2411239C2 (es)
TW (1) TW200635915A (es)
WO (1) WO2006069788A1 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds
GB0505969D0 (en) * 2005-03-23 2005-04-27 Novartis Ag Organic compounds
GB0510810D0 (en) * 2005-05-26 2005-06-29 Novartis Ag Organic compounds
GEP20115206B (en) 2005-05-27 2011-04-26 Actelion Pharmaceuticals Ltd Novel piperidine carboxylic acid amide derivatives
GB0514203D0 (en) 2005-07-11 2005-08-17 Novartis Ag Organic compounds
AU2006332124B2 (en) 2005-12-30 2011-03-03 Novartis Ag 3 , 5-substitgammaued piperidine compounds as renin inhibitors
BRPI0707349A2 (pt) 2006-02-02 2011-05-03 Actelion Pharmaceuticals Ltd composto, composição farmacêutica, e, uso de um composto
US7638541B2 (en) 2006-12-28 2009-12-29 Metabolex Inc. 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
EP2119702A4 (en) 2007-01-31 2010-12-08 Dainippon Sumitomo Pharma Co amide derivative
WO2008128832A1 (en) * 2007-04-18 2008-10-30 Nicox S.A. Nitroderivatives of non-peptidic renin inhibitors for the treatment of cardiovascular, renal and chronic liver disease, inflammations and metabolic syndrome
CA2688057A1 (en) * 2007-05-24 2008-11-27 Merck Frosst Canada Ltd. Novel case of renin inhibitors
TWI452044B (zh) * 2007-06-15 2014-09-11 Mitsubishi Tanabe Pharma Corp 嗎啉衍生物
NZ582098A (en) 2007-06-25 2012-03-30 Novartis Ag N5-(2-ethoxyethyl)-n3-(2-pyridinyl)-3,5-piperidinedicarboxamide derivatives for use as renin inhibitors
JP5489997B2 (ja) 2007-07-19 2014-05-14 シマベイ セラピューティクス， インコーポレーテッド 糖尿病および代謝疾患の治療のためのＲＵＰ３またはＧＰＲｌ１９受容体のアゴニストとしてのＮ−アザ環状置換ピロール、ピラゾール、イミダゾール、トリアゾールおよびテトラゾール誘導体
CN101842349B (zh) * 2007-11-01 2013-07-17 宇部兴产株式会社 磺酸苯酯化合物、使用它的非水电解液及锂电池
TWI434690B (zh) * 2007-12-19 2014-04-21 Dainippon Sumitomo Pharma Co 雜雙環衍生物
WO2009127949A1 (en) * 2008-04-17 2009-10-22 Pfizer Inc. 4- [3- (aryloxy) benzylidene] -3-methyl piperidine aryl carboxamide compounds useful as faah inhibitors
ES2548134T3 (es) 2008-05-05 2015-10-14 Actelion Pharmaceuticals Ltd. Derivados de piperidina 3,4-sustituida como inhibidores de renina
GEP20166443B (en) 2008-06-19 2016-03-10 Takeda Pharmaceutical Heterocyclic compound and use thereof
AU2009271414A1 (en) * 2008-06-20 2010-01-21 Metabolex, Inc. Aryl GPR119 agonists and uses thereof
WO2010066028A1 (en) * 2008-12-10 2010-06-17 Merck Frosst Canada Ltd. 3,4 - substituted piperidine derivatives as renin inhibitors
US8754008B2 (en) * 2009-06-19 2014-06-17 Basf Se Herbicidal benzoxazinones
US8658639B2 (en) * 2009-06-24 2014-02-25 Dainippon Sumitomo Pharma Co., Ltd N-substituted-cyclic amino derivative
TWI472524B (zh) * 2009-09-28 2015-02-11 Actelion Pharmaceuticals Ltd 腎素抑制劑
ES2497566T3 (es) 2009-10-01 2014-09-23 Cymabay Therapeutics, Inc. Sales de tetrazol-1-il-fenoximetil-tiazol-2-il-piperidinil-pirimidina sustituida
WO2011163090A1 (en) 2010-06-23 2011-12-29 Metabolex, Inc. Compositions of 5-ethyl-2-{4-[4-(4-tetrazol-1-yl-phenoxymethyl)-thiazol-2-yl]-piperidin-1-yl}-pyrimidine
HUE037584T2 (hu) 2011-03-16 2018-09-28 Mitsubishi Tanabe Pharma Corp Nitrogéntartalmú telített heterociklusos vegyület
CA2881479A1 (en) 2012-08-16 2014-02-20 Ohio State Innovation Foundation Stat3 inhibitors and their anticancer use
WO2014042263A1 (ja) 2012-09-14 2014-03-20 田辺三菱製薬株式会社 新規レニン阻害薬
US20160137639A1 (en) * 2012-10-26 2016-05-19 Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof
FR3002736B1 (fr) * 2013-03-04 2015-06-26 Virbac Composition orale nutritionnelle et medicamenteuse a usage veterinaire
CN103524511A (zh) * 2013-10-21 2014-01-22 南京邮电大学 2,7,12-三溴-5,10,15-三烷基三并咔唑的制备方法
US10292983B2 (en) 2016-08-03 2019-05-21 Cymabay Therapeutics, Inc. Oxymethylene aryl compounds for treating inflammatory gastrointestinal diseases or gastrointestinal conditions
CN111423411B (zh) * 2020-04-02 2021-04-16 南京生命源医药科技有限公司 一种新型肾素抑制剂

Family Cites Families (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3278541A (en) * 1966-10-11 Di-substituted-n-alkyl piperidines
US4559337A (en) 1985-02-25 1985-12-17 G.D. Searle & Co. 8-Chlorodibenz[b,f][1,4]oxazepine-10(11H)-carboxylic acid, 2-(alkoxy-containing acyl)hydrazides
TW224941B (es) 1989-11-08 1994-06-11 Yamanouchi Pharma Co Ltd
SK56296A3 (en) 1993-11-09 1997-02-05 Merck & Co Inc Piperidinal, pyrrolidinal and hexahydro-1h-azepinal derivatives, manufacturing process thereof and pharmaceutical compositions containing them
US5721251A (en) 1993-12-10 1998-02-24 Merck & Co., Inc. Piperidine, pyrrolidine and hexahydro-1H-azepines promote release of growth hormone
DE69523182T2 (de) * 1995-06-06 2002-02-07 Pfizer Substituierte n-(indol-2-carbonyl)-glycinamide und derivate als glycogen phosphorylase inhibitoren
KR100384979B1 (ko) 1995-09-07 2003-10-17 에프. 호프만-라 로슈 아게 심부전증및신부전증치료용의신규한4-(옥시알콕시페닐)-3-옥시-피페리딘
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US6225352B1 (en) 1996-08-14 2001-05-01 Warner-Lambert Company Low molecular weight dendritic compounds as pharmaceutical agents
JP4066004B2 (ja) * 1997-10-13 2008-03-26 忠弘 大見 上段部材取付けの基準となる孔を有する複数の下段部材の固定方法および固定用治具
CA2346537A1 (en) 1998-10-07 2000-04-13 Gian Luca Araldi Monomeric and dimeric heterocycles, and therapeutic uses thereof
WO2000063173A1 (en) 1999-04-14 2000-10-26 F. Hoffmann-La Roche Ag Process for the preparation of substituted piperidines
US6197959B1 (en) 1999-04-27 2001-03-06 Hoffmann-La Roche Inc. Piperidine derivatives
US6376672B1 (en) 1999-04-27 2002-04-23 Hoffmann-La Roche Inc. Naphthalenylmethoxypiperidines as renin inhibitors
WO2002076440A2 (en) 2001-03-23 2002-10-03 Elan Pharmaceuticals, Inc. Methods of treating alzheimer's disease with piperidin derivates
WO2002088101A2 (en) * 2001-04-27 2002-11-07 Vertex Pharmaceuticals Incorporated Inhibitors of bace
SI1465861T1 (sl) 2001-12-20 2009-12-31 Bristol Myers Squibb Co Alfa-(n-sulfonamido)acetamidni derivati kot beta-amiloid inhibitorji
WO2003093267A1 (en) 2002-04-29 2003-11-13 Actelion Pharmaceuticals Ltd 7-aryl-3,9-diazabicyclo(3.3.1)non-6-ene derivatives and their use as renin inhibitors in the treatment of hypertension, cardiovascular or renal diseases
US20030216441A1 (en) 2002-05-10 2003-11-20 Gwaltney Stephen L. Farnesyltransferase inhibitors
AU2003229746A1 (en) * 2002-06-27 2004-01-19 Actelion Pharmaceuticals Ltd Novel tetrahydropyridine derivatives as renin inhibitors
AU2003299791A1 (en) * 2002-12-20 2004-07-22 Bayer Pharmaceuticals Corporation Substituted 3,5-dihydro-4h-imidazol-4-ones for the treatment of obesity
US20040214832A1 (en) 2003-04-10 2004-10-28 Cuiman Cai Piperazine derivative renin inhibitors
US20040204455A1 (en) 2003-04-10 2004-10-14 Cody Wayne Livingston Piperidine derivative rennin inhibitors
US20060217371A1 (en) 2003-04-28 2006-09-28 Olivier Bezencon Diazabicyclononene and tetrahydropyriddine derivatives as renin inhibitors
EP1620403B1 (en) 2003-04-29 2007-11-28 Actelion Pharmaceuticals Ltd. Novel 3,4-disubstituted 1,2,3,6-tetrahydropyridine derivatives
EP1622907A1 (en) 2003-04-30 2006-02-08 Actelion Pharmaceuticals Ltd. Azabicyclononene derivatives
US20060258648A1 (en) 2003-04-30 2006-11-16 Olivier Bezencon 9-Azabicyclo'3.3.1 inon-6-ee derivatives with a heteroatom at the 3-position as renin inhibitors
EP1622901A1 (en) 2003-04-30 2006-02-08 Actelion Pharmaceuticals Ltd. Tropane derivatives and their use as ace inhibitors
AU2004233577A1 (en) 2003-05-02 2004-11-11 Actelion Pharmaceuticals Ltd. Diazabicyclononene derivatives
GB0319124D0 (en) 2003-08-14 2003-09-17 Smithkline Beecham Corp Chemical compounds
TW200900399A (en) 2003-10-01 2009-01-01 Speedel Experimenta Ag Organic compounds
WO2005051911A1 (en) 2003-11-26 2005-06-09 Novartis Ag 4-phenylpiperidine derivatives as renin inhibitors
TW200613274A (en) 2004-07-09 2006-05-01 Speedel Experimenta Ag Organic compounds
GB0428250D0 (en) 2004-12-23 2005-01-26 Novartis Ag Organic compounds
GB0428526D0 (en) 2004-12-30 2005-02-09 Novartis Ag Organic compounds

Also Published As

Publication number Publication date
RU2007129090A (ru) 2009-02-10
EP2177518A1 (en) 2010-04-21
EP1833816B1 (en) 2009-11-11
ATE448217T1 (de) 2009-11-15
AU2005321475A1 (en) 2006-07-06
ES2336470T3 (es) 2010-04-13
EP1833816A1 (en) 2007-09-19
JP5188814B2 (ja) 2013-04-24
GT200500359A (es) 2006-07-17
JP2008526701A (ja) 2008-07-24
US20110263560A1 (en) 2011-10-27
CA2587348A1 (en) 2006-07-06
PL1833816T3 (pl) 2010-04-30
CN101094848A (zh) 2007-12-26
US8084450B2 (en) 2011-12-27
AR052446A1 (es) 2007-03-21
BRPI0519769A2 (pt) 2009-02-17
TW200635915A (en) 2006-10-16
PT1833816E (pt) 2010-02-17
CN101094848B (zh) 2013-03-13
DE602005017665D1 (de) 2009-12-24
US20090312304A1 (en) 2009-12-17
KR20070091174A (ko) 2007-09-07
US8178559B2 (en) 2012-05-15
GB0428526D0 (en) 2005-02-09
WO2006069788A1 (en) 2006-07-06
MX2007008078A (es) 2007-07-24
RU2411239C2 (ru) 2011-02-10
AU2005321475B2 (en) 2009-11-12

Similar Documents

Publication Publication Date Title
PE20061332A1 (es) Derivados de piperidina como agentes inhibidores de la renina
PE20060381A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
CO5570660A2 (es) Indazolilpirrolotriazinas c-6 modificadas
DE60225671D1 (de) Pharmazeutisch wirksame piperidinderivate
AR034268A1 (es) Compuestos derivados de piperidina, su uso en preparacion de medicamentos, composicion farmaceutica, metodo de tratamiento y proceso para su preparacion
UY27503A1 (es) Nuevos derivados de piperazina
PE20071136A1 (es) Derivados de anilina sustituida como antagonistas de la histamina h3
ATE388958T1 (de) 4'-c-substituierte 2-haloadenosinderivate
CY1106522T1 (el) Ετepοκυκλικη ενωση και αντικαρκινικο μεσο που πepιεχει την ιδια ως δραστικο συστατικο
UY28423A1 (es) Inhibidores de proteasas serinas, en especial proteasa ns3-ns4a del vhc.-
DE60324544D1 (de) Muskarin antagonisten
PE20061106A1 (es) Derivados de 2-(4-oxo-4h-quinazolin-3-il)acetamida
PE20060737A1 (es) 3-AMINO-PIRAZOL[3,4b] PIRIDINAS COMO INHIBIDORES DE PROTEINTIROSINQUINASAS Y SU PREPARACION
HUP0400246A2 (hu) 1,2,4-Trioxolánt tartalmazó maláriaellenes gyógyszerkészítmények és eljárás az előállításukra és az alkalmazásukra
DE602005023015D1 (de) Indolderivate als viruzide
TW200611687A (en) Pharmaceutical compositions used for immunosuppressant
MXPA05009611A (es) Piperidinas sustituidas como nuevos inhibidores de mdm2-p53.
DE602006011752D1 (de) Als antikoagulationsmittel geeignete phenylglycinamid- und pyridylglycinamidderivate
UY29312A1 (es) Piperazin-1-carboxamidas n,4,sustituidas y sus derivados, composiciones que los contienen, procedimientos de preparación y aplicaciones
CR10974A (es) Inhibidores de carboxipeptidasa b plasmatica (divisional)
NO20052074L (no) Substituerte benzoksazinoner og anvendelser derav.
DE60313350D1 (de) Pyrimidin-2,4-dion-derivate als matrix-metalloproteinase-hemmer
UA85502C2 (en) Diazaindole-dicarbonyl-piperazinyl antiviral agents
MXPA04006041A (es) Antivirales de piridoquinoxalina.
BR0213731A (pt) Compostos de silìcio

Legal Events

Date Code Title Description
FA Abandonment or withdrawal